10e8.4/imab
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 5, 2019 (NCT03875209)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-cell surface antigen CD4ANTAGONIST
CD4 antagonist
- GP41INHIBITOR
HIV1 ENV inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05890963 | Phase 1 | Nov 28, 2023 | Columbia University, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT03875209 | Phase 1 | Apr 5, 2019 | Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, Rockefeller University, The EMMES Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 0 | 1 | 2023 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Rockefeller University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2019 |
| United States Army | Government | 1 | 0 | 1 | 2023 |
7 organizations
Page 1 / 1